July 28, 2011 – Chalfont, Pennsylvania – Genomind, LLC (www.genomind.com) awarded an education grant to the Neuroscience Education Institute (NEI) for the purpose of funding one of NEI’s well-known “Expert Clinical Cases” (ECC) Series, an online CME program in psychopharmacology. The three cases in the series, now available for CME credit on the www.neiglobal.com website, explore the potential application of genotyping to personalized treatment in psychiatry. The three cases include: (1) a 59-year-old with hidden bipolarity; (2) a 55-year-old with depression not responsive to serotonergic treatment; and (3) a 54-year-old with recurrent depression and psychiatric Parkinsonism.
The ECC Series are actual patient cases from the files of NEI’s distinguished faculty. All three cases identify the potential use of pharmacogenetics for optimal patient care, identify the genetic polymorphisms associated with various mental health disorders and treatment responses, and utilize currently available pharmacogenetic data to inform best practices in mental health.
“We strongly support the work of NEI to bring interactive learning to mental health professionals, and to provide education on psychopharmacology,” said Jay Lombard, DO, Chief Scientific Officer and Medical Director for Genomind. “NEI brings the most recent advances in science, such as the use of genotyping in psychiatry, to its curriculum, training programs, and membership.”
“Personalized medicine has the potential to increase the quality and reduce the economic burden of healthcare and is likely to become a valuable tool for the preventative and therapeutic care of diseases,” said Stephen Stahl, MD, Chairman, Neuroscience Education Institute. “Clinicians need to be informed of the advances being made in personalized medicine as we gain more information about the human genome.”
About Genomind, LLC: Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by providing genetic information to better understand the patient. Genomind was founded by Ronald I Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. He also is founder of ValueOptions, one of the nation’s leading behavioral health and wellness companies. Dr Jay Lombard, a neurologist, is co-founder of Genomind and is a nationally recognized leader in neuropsychiatry practice, research, and thought leadership. They are supported in their work by a Scientific Advisory Board comprised of internationally recognized researchers and thought leaders in psychiatry and neurology. Learn more at www.genomind.com.
About the Neuroscience Education Institute: NEI was founded in 2000 by award-winning author and psychiatrist Dr. Stephen M. Stahl. NEI provides interactive learning to mental health clinicians worldwide. Through NEI’s fast-growing Global Psychopharmacology Congress, its web-based CME activities, and its online resources, NEI simplifies complex concepts to enhance understanding for US and international clinicians. NEI Members and Guests have access to www.NEIglobal.com, an online resource focused on the essentials of psychopharmacology. Learn more at www.NEIglobal.com.
